von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women

Summary

ADAMTS13 dysfunction has been involved in the pathogenesis of Thrombotic Thrombocytopenic Purpura. This disorder occurs more frequently in women and, in 13% of them, is associated with pregnancy. However, there is little information on the protease behaviour in normal pregnancy. We studied von Willebrand factor and ADAMTS13 activity changes in normal non-pregnant, pregnant and post-delivery women. Fifty-five non-pregnant women, normal blood bank donors, who were not taking contraceptive pills were included as controls. A prospective cross-sectional study of 270 normal pregnant and post-delivery women was carried out. ADAMTS13 activity decreased progressively as from the period of 12–16 weeks up to the end of early puerperium (mean 52%, range 22–89, p < 0.0001), to increase slightly thereafter. Nulliparous presented mildly lower levels of ADAMTS13 activity than parous women (65% vs. 83%, p=0.0003), and primigravidae than multigravidae between 6–11 weeks up to 17–23 weeks of pregnancy (69% vs. 80%, p=0.005). Although in all women the protease levels were the same by blood groups, the O blood group non-pregnant women showed a higher mean of ADAMTS13 activity than those non-O (78% vs. 69%, p= 0.064). Our results suggest that the changing levels of protease activity during pregnancy and puerperium, induced by unidentified mechanisms, could render the peripartum time more vulnerable to developed thrombotic microangiopathies.

Keywords

ADAMTS13 activity - normal women - pregnancy - puerperium

• References

• 1 Moake JL, Rudy CK, Troll JH. et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-5.
• 2 Tsai H. Physiologic cleavage on von Willebrand factor by a plasma protease is dependent on the conformation and requires calcium ion. Blood 1996; 87: 4235-44.
• 3 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vitro proteolysis. Blood 1996; 87: 4223-34.
• 4 Dent JA, Berkowitz SD, Ware J. et al. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA 1990; 87: 6306-10.
• 5 Levy GG, Nichols WC, Lian EC. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-94.
• 6 Bell WR, Braine HG, Ness PM. et al. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. N Engl J Med 1991; 325: 398-403.
• 7 Thompson CE, Damon LE, Ries CA. et al. Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood 1992; 80: 1890-5.
• 8 Hayward CPM, Sutton DMC, Carter Jr WH. et al. Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Arch Intern Med 1994; 154: 982-7.
• 9 Lara Jr PN, Coe TL, Zhou H. et al. Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpurahemolytic uremic syndrome. Am J Med 1999; 107: 573-9.
• 10 McNinn JR, George JN. Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancy. J Clin Apheresis 2001; 16: 202-9.
• 11 Vesely SK, George JN, Lämmle B. et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 60-68.
• 12 Fuchs WE, George JN, Dotin LN. et al. Thrombotic thrombocytopenic purpura. Occurrence two years apart during late pregnancy in two sisters. JAMA 1976; 235: 2126-7.
• 13 Witznitzer A, Mazor M, Lieberman JR. et al. Familial occurrence of thrombotic thrombocytopenic purpura in two sisters during pregnancy. Am J Obstet Gynecol 1992; 166: 20-21.
• 14 Alqadah F, Zebeib MA, Awidi AS. Thrombotic thrombocytopenic purpura associated to pregnancy in two sisters. Postgrad Med J 1993; 69: 229-31.
• 15 Holdrinet RS, de Pauw BE, Haanen C. Hormonal dependence of thrombotic thrombocytopenic purpura (TTP). Scand J Haematol 1983; 30: 250-6.
• 16 Mannucci PM, Canciani MT, Forza I. et al. Changes in health and disease of metalloprotease that cleaves von Willebrand factor. Blood 2001; 98: 2730-5.
• 17 Kempfer AC, Silaf MR, Farias CE. et al. Binding of von Willebrand factor to collagen by flow cytometry. Am J Clin Pathol 1999; 111: 418-23.
• 18 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52.
• 19 Thorell L, Blombäck B. Purification of the FVIII complex. Thromb Res 1984; 35: 431-49.
• 20 Furlan M, Robles R, Galbusera M. et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84.
• 21 Gerritsen HE, Turecek PL, Schwarz HP. et al. Assay of von Willebrand Factor (vWF)-cleaving Protease based on decreased collagen binding affinity of degraded vWF. Thromb Haemost 1999; 82: 1386-9.
• 22 Taylor LD. The application of the biotin/ avidin system to the von Willebrand factor antigen immunoassay. Thromb Haemost 1988; 59: 251-4.
• 23 Hubbard AR, Sands D, Chang AC. et al. Standardisation of von Willebrand Factor in therapeutic concentrates: calibration of the 1st International Standard for von Willebrand Factor concentrate (00/514). Thromb Haemost 2002; 88: 380-6.
• 24 Neugebauer BM, Goy C, Budek I, Seitz R. Comparison of two von Willebrand Factor collagen-binding assays with different binding affinities for low, medium, and high multimers of von Willebrand Factor. Semin Thromb Hemost 2002; 28: 139-47.
• 25 Sánchez-Luceros A, Meschengieser SS, Marchese C. et al. Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium. Blood Coagul Fibrinolysis 2003; 14: 647-51.
• 26 Raife TJ, Montgomery RR. von Willebrand factor and thrombotic thrombocytopenic purpura. Curr Opin Hematol 2000; 07: 278-283.
• 27 George JN. The association of pregnancy with thrombotic thrombocytopenic purpura– hemolytic uremic syndrome. Curr Opin Hematol 2003; 10: 339-44.
• 28 Lattuada A, Rossi E, Calzarossa C. et al. Mild to moderate reduction of von Willebrand factor clearing protease (ADAMTS13) in pregnant women with HELLP microangiopathies. Haematologica 2003; 88: 1029-34.
• 29 Coppola R, Mari D, Lattuada A. et al. von Willebrand factor in Italian centenarians. Haematologica 2003; 88: 39-43.
• 30 Reiter RA, Knöbl P, Varadi K. et al. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood 2003; 101: 946-8.
• 31 Bernstein L, Pike MC, Ross RK. et al. Estrogen and sex hormone-binding globulin levels in nulliparous and parous women. J Natl Cancer Inst 1985; 74: 741-5.
• 32 Bernstein L, Depue RH, Ross RK. et al. Higher maternal levels of free estradiol in first compared to second pregnancy: early gestational differences. J Natl Cancer Inst 1986; 76: 1035-9.
• 33 Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 2003; 01: 33-40.
• 34 Bowen DJ. Genome-wide linkage analysis of von Willebrand factor plasma levels implicates the ABO locus as a principal determinant: should we overlook ADAMTS13?. Thromb Haemost 2003; 90: 961.
• 35 McCrae KR. Thrombocytopenia in pregnancy: differential diagnosis, pathogenesis, and management. Blood Rev 2003; 17: 7-14.
• 36 Nicol KK, Shelton BJ, Knovich MA. et al. Overweight individuals are at increased risk for thrombotic thrombocytopenic purpura. Am J Hematol 2003; 74: 170-4.